Immunotherapy for Alzheimer's disease

T Wisniewski, F Goñi - Biochemical pharmacology, 2014 - Elsevier
Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the
normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The …
被引用次数：131 相关文章

Immunotherapy for Alzheimer's disease.

T Wisniewski, F Goñi - Biochemical Pharmacology, 2014 - europepmc.org
Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the
normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The …

[引用][C] Immunotherapy for Alzheimer's disease

T Wisniewski, F Goñi - Biochemical Pharmacology, 2014 - cir.nii.ac.jp
Immunotherapy for Alzheimer's disease | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす …
[HTML] nih.gov

[HTML][HTML] Immunotherapy for Alzheimer's Disease

T Wisniewski, F Goni - Biochemical pharmacology, 2014 - ncbi.nlm.nih.gov
Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the
normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The …
[PDF] academia.edu

[PDF][PDF] Immunotherapy for Alzheimer's Disease

T Wisniewski, F Goni - Biochem Pharmacol, 2014 - academia.edu
Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the
normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The …

Immunotherapy for Alzheimer's disease

T Wisniewski, F Goñi - Biochemical pharmacology, 2014 - pubmed.ncbi.nlm.nih.gov
Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the
normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The …

Immunotherapy for Alzheimer's disease

T Wisniewski, F Goñi - Biochemical Pharmacology, 2014 - infona.pl
Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the
normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The …